Vistagen enrolls first patient in PALISADE-3 Phase 3 fasedienol trial for social anxiety disorder

Vistagen Therapeutics, Inc.

PALISADE-3 is a randomized, double-blind, placebo-controlled study of ~236 adults aged 18–65 with SAD.
Primary endpoint is patient-rated SUDS; patients randomized 1:1 to fasedienol or placebo.
Follows positive PALISADE-2 results; PALISADE-4 replication planned for H2 2024.
Social anxiety disorder affects over 25 million Americans; fasedienol is an investigational pherine.
CEO Shawn Singh calls the initiation a 'major milestone' toward first-in-class treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.